Advancing Healthcare Energy: Olympus Awarded PROVISTA Contract

Provista

Olympus announced today that it has been awarded a contract for its advanced energy portfolio by Provista Inc. This new, nationwide agreement provides Provista members with negotiated pricing for Olympus® energy products, including the POWERSEAL™ sealer/divider, the SONICBEAT™ ultrasonic portfolio and THUNDERBEAT™ hybrid energy portfolio.

The multi-year agreement was effective as of July 1, 2023.

The Olympus advanced energy portfolio is available under this contract, including:

  • The Universal Surgical Energy Generator (EPF-1), which provides common forms of surgical energy and eliminates the need for multiple generators.
  • The SONICBEAT Ultrasonic Energy Portfolio, which offers precise dissection with 5mm sealing and secure tissue grasping thanks to unique wiper jaw design.1
  • The THUNDERBEAT Hybrid Energy Portfolio, which offers efficiency through fast cutting and versatility and 7mm sealing and precise dissection.2
  • The POWERSEAL Sealer/Divider, which features a curved, tapered and double-action Maryland dissector/grasper design and vessel sealing up to and including 7mm, including pulmonary vessels, tissue bundles and lymphatics.3

Jay Sullivan, Group Vice President, Enterprise Solutions, Medical Systems Group, Olympus

“Contract awards are important to our business. But even more important is that the Provista awards create opportunities for customers such as ASCs to access state-of-the-art equipment toward improving patient care in a value-based framework. The ASC market is important for healthcare providers and the communities they serve, and we are focused on growing our presence there.”

Energy Options Offered Through Olympus

Olympus offers an array of energy options such as the THUNDERBEAT hybrid energy devices portfolio that deliver ultrasonic and bipolar energy simultaneously for tissue management, including hemostatic cutting and dissection, in laparoscopic surgery and open surgery. Olympus’ POWERSEAL devices can be used in general surgery and gynecological, colorectal, bariatric, urological, thoracic and vascular surgical procedures.

EPF-1 Generator

The EPF-1 generator, with its accessories and ancillary equipment, is intended for cutting and coagulation of tissue in open, laparoscopic and endoscopic surgery and should only be used by a qualified physician in an adequate medical environment.  Improper use or use of incompatible equipment with these generators may lead to excessive or incorrect HF and cause thermal or other injuries for the patient and/or operator.

All plugs must be securely inserted into the corresponding sockets for proper use. Be aware that if the main plug is accidentally disconnected during a procedure, the electrosurgical generator immediately turns off and this may result in complications for the patient should it occur during energy delivery. Please refer to the instructions for use prior to usage.

References

1 Data on file with Olympus (869-2368, 869-2512)
2 Data on file with Olympus (868-4375, 868-4378, 868-3710)
3 Data on file with Olympus (DN004705, DN0044706)

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”